Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Insulin aspart: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 09:34, 6 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 464210466 of page Insulin_aspart for the Chem/Drugbox validation project (updated: 'UNII', 'ChEMBL', 'CAS_number').  Latest revision as of 21:40, 27 November 2024 edit Di (they-them) (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers21,903 edits it's unnecessary for an image caption to say "this is a picture" 
Line 1: Line 1:
{{Short description|Rapid-acting man-made insulin}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Use dmy dates|date=August 2021}}
{{Drugbox
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 458271391 | verifiedrevid = 464363109
| IUPAC_name =
| image = Insulin Aspart Structural Formula.gif | image = Insulin Aspart Structural Formula.gif
| alt = <!-- Clinical data -->
| drug_name = Insulin Aspart
| tradename = NovoLog, NovoRapid, Fiasp, others

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|monograph|insulin_aspart}} | Drugs.com = {{drugs.com|monograph|insulin_aspart}}
| MedlinePlus = a605013 | MedlinePlus = a605013
| DailyMedID = Insulin_aspart
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C | pregnancy_AU = A
| pregnancy_AU_comment = <ref name=Preg2019 /><ref name="Truvelog APMDS" /><ref name="Insulin aspart APAR">{{cite web |url=https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-200301.pdf |title=Australian Public Assessment Report for Insulin aspart |date=March 2021 |publisher=] (TGA) |archive-url=https://web.archive.org/web/20210624194925/https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-200301.pdf |archive-date=24 June 2021}}</ref><ref>{{cite web |url=https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-rys-200827.pdf |title=Australian Public Assessment Report for Insulin aspart (rys) |publisher=] (TGA) |date=August 2021 |archive-url=https://web.archive.org/web/20220205044655/https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-rys-200827.pdf |archive-date=5 February 2022}}</ref>
| pregnancy_category =
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| routes_of_administration = ], ]
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| ATC_prefix = A10
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| ATC_suffix = AB05
| biosimilars = Kirsty,<ref name="Kirsty EPAR" /> Trurapi,<ref>{{cite web | title=Approved in 2020: Drugs for human use | website=] | date=26 July 2021 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2020/approved-2020-drugs-human-use.html | access-date=27 March 2024}}</ref> Truvelog<ref name="Truvelog APMDS" />
| legal_AU = S4
| legal_AU_comment = <ref name="Truvelog APMDS" /><ref name="Insulin aspart APAR" /><ref name="Truvelog Solostar ARTG" />
| legal_CA = Rx-only
| legal_CA_comment = /&nbsp;Schedule D<ref>{{cite web | title=Regulatory Decision Summary - Fiasp | website=] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00206 | access-date=4 June 2022 | archive-date=5 June 2022 | archive-url=https://web.archive.org/web/20220605060721/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00206 | url-status=live }}</ref><ref>{{cite web | title=Regulatory Decision Summary - Trurapi | website=] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00708 | access-date=4 June 2022 | archive-date=5 June 2022 | archive-url=https://web.archive.org/web/20220605060621/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00708 | url-status=live }}</ref><ref>{{cite web | title=Diabetic health | website=] | date=8 May 2018 | url=https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/diabetic-health.html | access-date=13 April 2024}}</ref>
| legal_UK = POM
| legal_UK_comment = <ref name="NovoRapid SmPC" />
| legal_US = Rx-only | legal_US = Rx-only
| legal_US_comment = <ref name="Fiasp FDA label">{{cite web | title=Fiasp- insulin aspart injection injection, solution | website=DailyMed | date=19 December 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834e7efc-393f-4c55-9125-628562a8a5cf | access-date=12 November 2020 | archive-date=13 November 2020 | archive-url=https://web.archive.org/web/20201113025955/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834e7efc-393f-4c55-9125-628562a8a5cf | url-status=live }}</ref><ref name="NovoLog FDA label">{{cite web | title=NovoLog- insulin aspart injection, solution Insulin Diluting Medium For NovoLog- water injection injection, solution | website=DailyMed | date=15 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1e73a2-3009-40d0-876c-b4cb2be56fc5 | access-date=12 November 2020 | archive-date=12 November 2020 | archive-url=https://web.archive.org/web/20201112193904/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1e73a2-3009-40d0-876c-b4cb2be56fc5 | url-status=live }}</ref><ref name="NovoLog Mix FDA label">{{cite web | title=NovoLog Mix 70/30- insulin aspart injection, suspension | website=DailyMed | date=15 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1861fcee-7673-4afe-a206-08fa05c0add2 | access-date=12 November 2020 | archive-date=29 September 2020 | archive-url=https://web.archive.org/web/20200929013529/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1861fcee-7673-4afe-a206-08fa05c0add2 | url-status=live }}</ref>
| legal_status =
| legal_EU = Rx-only
| routes_of_administration = Subcutaneous
| legal_EU_comment = <ref name="NovoMix EPAR" /><ref name="Kirsty EPAR" /><ref name="Truvelog Mix 30 EPAR" />
| legal_status = Rx-only


<!--Pharmacokinetic data--> <!-- Pharmacokinetic data -->| bioavailability =
| bioavailability = | protein_bound =
| protein_bound = | metabolism =
| metabolism = | onset = 15 minutes
| elimination_half-life = | elimination_half-life =
| duration_of_action = 3–5 hours
| excretion =
| excretion = <!-- Identifiers -->

<!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA
| CAS_number_Ref = {{cascite|changed|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = <!-- blanked - oldvalue: 116094-23-6 --> | CAS_number = 116094-23-6
| ATC_prefix = A10
| ATC_suffix = AB05
| PubChem = 16132418 | PubChem = 16132418
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01306 | DrugBank = DB01306
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|changed|FDA}} | UNII_Ref = {{fdacite|changed|FDA}}
| UNII = <!-- blanked - oldvalue: D933668QVX --> | UNII = D933668QVX
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04475 | KEGG = D04475
| ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1201496 --> | ChEMBL = 1201496

| C=256 | H=381 | N=65 | O=79 | S=6
<!-- Chemical data -->| C = 256
| molecular_weight = 5825.8 g/mol
| H = 381
| N = 65
| O = 79
| S = 6
}} }}

<!-- Definition and medical uses -->
'''Insulin aspart''', sold under the brand name '''NovoLog''', among others, is a ] type of ] used to treat ] and ].<ref name=AHFS2019/> It is generally used by ] but may also be used by ].<ref name=AHFS2019/> Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.<ref name=AHFS2019/> Generally a longer-acting insulin like ] is also needed.<ref name=AHFS2019/>

<!-- Side effects and mechanisms -->
Common side effects include ], ], ], and pain at the site of injection.<ref name=AHFS2019/> Other serious side effects may include ].<ref name=AHFS2019/> Use in ] and ] is generally safe.<ref name=Preg2019>{{cite web |title=Insulin aspart Pregnancy and Breastfeeding Warnings |url=https://www.drugs.com/pregnancy/insulin-aspart.html |website=Drugs.com |access-date=3 March 2019 |archive-date=6 March 2019 |archive-url=https://web.archive.org/web/20190306174903/https://www.drugs.com/pregnancy/insulin-aspart.html |url-status=live }}</ref> It works the same as ] by increasing the amount of ] that tissues take in and decreasing the amount of glucose made by the liver.<ref name=AHFS2019>{{cite web |title=Insulin Aspart Monograph for Professionals |url=https://www.drugs.com/monograph/insulin-aspart.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=3 March 2019 |language=en |archive-date=6 March 2019 |archive-url=https://web.archive.org/web/20190306234812/https://www.drugs.com/monograph/insulin-aspart.html |url-status=live }}</ref> It is a manufactured form of human insulin; where a single ] has been changed, specifically a ] with an ] at the B28 position.<ref>{{cite book |vauthors=Turner JR |title=New Drug Development: An Introduction to Clinical Trials: Second Edition |date=2010 |publisher=Springer Science & Business Media |isbn=9781441964182 |page=32 |url=https://books.google.com/books?id=Rv10neRV3R8C&pg=PA32 |access-date=11 September 2020 |archive-date=20 April 2021 |archive-url=https://web.archive.org/web/20210420140538/https://books.google.com/books?id=Rv10neRV3R8C&pg=PA32 |url-status=live }}</ref>

<!-- History and culture -->
Insulin aspart was approved for medical use in the United States in 2000.<ref name=AHFS2019/> In 2022, it was the 76th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Insulin Aspart Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/InsulinAspart | access-date = 30 August 2024 }}</ref> Manufacturing involves ], which have had the ] for insulin aspart put into their ].<ref>{{cite book | vauthors = Banga AK |title=Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Second Edition |date=2005 |publisher=CRC Press |isbn=9781420039832 |page=13 |url=https://books.google.com/books?id=CckrBgAAQBAJ&pg=PA13 |access-date=11 September 2020 |archive-date=20 April 2021 |archive-url=https://web.archive.org/web/20210420140539/https://books.google.com/books?id=CckrBgAAQBAJ&pg=PA13 |url-status=live }}</ref> This yeast then makes the insulin, which is harvested from the ].<ref>{{cite book | vauthors = Schmid RD, Schmidt-Dannert C |title=Biotechnology: An Illustrated Primer |date=2016 |publisher=John Wiley & Sons |isbn=9783527677566 |page=222 |url=https://books.google.com/books?id=V5bNCwAAQBAJ&pg=PA222 |access-date=11 September 2020 |archive-date=20 April 2021 |archive-url=https://web.archive.org/web/20210420140538/https://books.google.com/books?id=V5bNCwAAQBAJ&pg=PA222 |url-status=live }}</ref>

== Medical uses ==
Insulin aspart is ] to improve glycemic control in people with diabetes.<ref name="Fiasp FDA label" /><ref name="NovoLog FDA label" />

=== Onset of action ===
The onset of action is approximately fifteen minutes, the peak action is reached in 45–90 minutes, and the duration is 3–5 hours.<ref name="NovoLog FDA label" />

== Side effects ==
The safety of insulin aspart in people with diabetes is no different from that of regular insulin. The side effects that are commonly associated with insulin therapy include: allergic reactions, injection site irritation, rashes, and ].<ref name= www.novolog.com>{{cite web |url=http://www.novolog.com/questions-default.asp?s=faqs-6 |title=Novolog: most FAQ |access-date=18 April 2011 |archive-url=https://web.archive.org/web/20111003061851/http://www.novolog.com/questions-default.asp?s=faqs-6 |archive-date=3 October 2011 |url-status=dead }}</ref> The most common side effect is hypoglycemia. Long-term use of insulin, including insulin aspart, can cause ] at the site of repeated injections or infusion. To reduce the risk of lipodystrophy, rotate the injection sites within the same region. Weight gain can also occur with the use of insulin aspart and it has been attributed to anabolic effects of insulin and a decrease in ]. Use of insulin aspart has also been associated with sodium retention and ].<ref name="www.novo-pi.com">{{cite web |url=http://www.novo-pi.com/novolog.pdf |title=Novolog: insulin aspart (rDNA origin) injection |work=Novo Nordisk |access-date=18 April 2011 |archive-date=22 March 2011 |archive-url=https://web.archive.org/web/20110322204803/http://www.novo-pi.com/novolog.pdf |url-status=live }}</ref>

== Formulations ==
Insulin aspart can be used in an ] and insulin pen for ]. Additionally, it can be used with an ] such as the I-port.<ref>{{cite web|url=https://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605013.html |title=Aspart insulin (rDNA origin) injection |access-date=8 June 2007 |archive-url=https://web.archive.org/web/20070610074313/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605013.html |archive-date=10 June 2007 |url-status=dead }}</ref>

Insulin aspart has a more rapid onset, and a shorter duration of activity than normal human insulin.<ref name=www.fda.gov>{{cite web |url=https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_13_04_KP%20InsulinAspartFDAlabel102005.pdf |title=Novolog: insulin aspart |website=] |access-date=16 December 2019 |archive-date=17 May 2017 |archive-url=https://web.archive.org/web/20170517041656/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_13_04_KP%20InsulinAspartFDAlabel102005.pdf |url-status=live }}</ref> Insulin aspart can also be used with external ]s.<ref name="NovoLog FDA label" />
]

=== Variations ===

NovoLog Mix 70/30 is a product which contains 30% insulin aspart and 70% insulin aspart protamine.<ref name="NovoLog Mix FDA label" /> The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection.<ref name="NovoLog Mix FDA label" /> The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day.<ref>{{cite web | work = Rx List | title = NovoLog Mix 70/30 | date = 6 August 2008 | url = http://www.rxlist.com/novolog-mix-70-30-drug.htm | archive-url = https://web.archive.org/web/20090420190334/http://www.rxlist.com/novolog-mix-70-30-drug.htm | archive-date = 20 April 2009 }}</ref>

NovoLog Mix is marketed to be used with the ] FlexPen.<ref>{{cite web | work = Novo Nordisk | title = NovoLog Mix 70/30 | date = 2008 | url = http://www.novologmix70-30.com/starting-with-novolog-mix.asp | archive-url = https://web.archive.org/web/20090508145759/http://www.novologmix70-30.com/starting-with-novolog-mix.asp | archive-date = 8 May 2009 }}</ref> The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours.<ref name="Pharmaceutical Biotechnology">{{cite book | vauthors = Beals JM, DeFelippis MR, Kovach PM | chapter = Insulin | veditors = Crommelin DJ, Sindelar RD, Meibohm B | date = 2008 | title = Pharmaceutical Biotechnology: Fundamentals and Applications. | location = New York, NY | publisher = Informa Healthcare USA, Inc. | page = 265–280 (270) | isbn = 978-1-4200-4437-9 }}</ref> NovoLog Mix is marketed in some countries as NovoMix 30.<ref>{{cite web | title=NovoMix 30 FlexPen 100 units/ml - Summary of Product Characteristics (SmPC) | website=(emc) | date=27 March 2019 | url=https://www.medicines.org.uk/emc/product/1600/smpc | access-date=12 April 2020 | archive-date=13 April 2020 | archive-url=https://web.archive.org/web/20200413050707/https://www.medicines.org.uk/emc/product/1600/smpc | url-status=live }}</ref><ref name="NovoMix EPAR">{{cite web | title=NovoMix EPAR | website=] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/novomix | access-date=12 April 2020 | archive-date=13 April 2020 | archive-url=https://web.archive.org/web/20200413050741/https://www.ema.europa.eu/en/medicines/human/EPAR/novomix | url-status=live }}</ref>

NovoRapid is produced in '']'' by ].<ref name="NovoRapid SmPC">{{cite web | title=NovoRapid 100 units/ml in a vial - Summary of Product Characteristics (SmPC) | website=(emc) | date=25 May 2018 | url=https://www.medicines.org.uk/emc/product/7919/smpc | access-date=9 September 2020 | archive-date=16 January 2021 | archive-url=https://web.archive.org/web/20210116143931/https://www.medicines.org.uk/emc/product/7919/smpc | url-status=live }}</ref>

A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.<ref>{{cite journal | vauthors = Dutta D, Mohindra R, Mahajan K, Sharma M | title = Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis | journal = Diabetes & Metabolism Journal | volume = 47 | issue = 1 | pages = 72–81 | date = January 2023 | pmid = 35746893 | pmc = 9925142 | doi = 10.4093/dmj.2022.0035 }}</ref><ref>{{cite journal | vauthors = Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M, Mathieu C, Nørgaard K, Renard E, Wilmot EG | title = Use of fast-acting insulin aspart in insulin pump therapy in clinical practice | journal = Diabetes, Obesity & Metabolism | volume = 21 | issue = 9 | pages = 2039–2047 | date = September 2019 | pmid = 31144428 | pmc = 6773364 | doi = 10.1111/dom.13798 }}</ref><ref>{{cite journal | vauthors = Evans M, Wilkinson M, Giannpolou A | title = Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin | journal = Diabetes Therapy | volume = 10 | issue = 5 | pages = 1793–1800 | date = October 2019 | pmid = 31485918 | pmc = 6778592 | doi = 10.1007/s13300-019-00685-0 }}</ref>

== Biosimilars ==
In December 2020, the ] (CHMP) of the ] adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kixelle, intended for the treatment of diabetes.<ref>{{cite web | title=Kixelle: Pending EC decision | website=] (EMA) | date=10 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle | access-date=12 December 2020 | archive-date=12 December 2020 | archive-url=https://web.archive.org/web/20201212165133/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle | url-status=live }}</ref> The applicant for this medicinal product is Mylan IRE Healthcare Limited. Kixelle was approved for medical use in the European Union in February 2021.<ref>{{cite web | title=Kixelle EPAR | website=] (EMA) | date=9 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kixelle | access-date=16 March 2021 | archive-date=29 June 2021 | archive-url=https://web.archive.org/web/20210629235515/https://www.ema.europa.eu/en/medicines/human/EPAR/kixelle | url-status=live }}</ref> Kixelle was renamed to Kirsty.<ref name="Kirsty EPAR">{{cite web | title=Kirsty EPAR | website=] (EMA) | date=9 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kirsty-previously-kixelle | access-date=14 September 2021 | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915064025/https://www.ema.europa.eu/en/medicines/human/EPAR/kirsty-previously-kixelle | url-status=live }}</ref>

Trurapi was approved for medical use in Canada in October 2020.<ref>{{cite web | title=Summary Basis of Decision (SBD) for Trurapi | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00515&lang=en | access-date=29 May 2022 | archive-date=30 May 2022 | archive-url=https://web.archive.org/web/20220530050752/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00515&lang=en | url-status=live }}</ref>

Truvelog and Truvelog Solostar were approved for medical use in Australia in October 2020.<ref name="Truvelog APMDS">{{cite web | title=Truvelog | website=Therapeutic Goods Administration (TGA) | date=23 October 2020 | url=https://www.tga.gov.au/apm-summary/truvelog | access-date=12 June 2021 | archive-date=13 June 2021 | archive-url=https://web.archive.org/web/20210613062838/https://www.tga.gov.au/apm-summary/truvelog | url-status=live }}</ref><ref name="Truvelog Solostar ARTG">{{cite web | title=Truvelog Solostar ARTG | website=] (TGA) | url=https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=325474 | access-date=12 June 2021 | archive-date=13 June 2021 | archive-url=https://web.archive.org/web/20210613062838/https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=325474 | url-status=live }}</ref>

In October 2021, Kirsty was approved for medical use in Canada.<ref name="Kirsty SBD">{{cite web | title=Summary Basis of Decision (SBD) for Kirsty | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00570&lang=en | access-date=29 May 2022 | archive-date=29 May 2022 | archive-url=https://web.archive.org/web/20220529194843/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00570&lang=en | url-status=live }}</ref>

In February 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Truvelog Mix 30, intended for the treatment of diabetes.<ref name="Truvelog Mix 30: Pending EC decision" /> The applicant for this medicinal product is sanofi-aventis groupe.<ref name="Truvelog Mix 30: Pending EC decision">{{cite web | title=Truvelog Mix 30: Pending EC decision | website=European Medicines Agency | date=24 February 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/truvelog-mix-30 | access-date=27 February 2022 | archive-date=27 February 2022 | archive-url=https://web.archive.org/web/20220227042953/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/truvelog-mix-30 | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> It was approved for medical use in the European Union in April 2022.<ref name="Truvelog Mix 30 EPAR">{{cite web | title=Truvelog Mix 30 EPAR | website=European Medicines Agency | date=23 February 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/truvelog-mix-30 | access-date=16 June 2022 | archive-date=17 June 2022 | archive-url=https://web.archive.org/web/20220617060422/https://www.ema.europa.eu/en/medicines/human/EPAR/truvelog-mix-30 | url-status=live }}</ref><ref>{{cite web | title=Truvelog Mix 30 Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1639.htm | access-date=3 March 2023}}</ref>

== Society and culture ==
{{As of|2018}}, there is a lack of compelling evidence to conclude superiority of insulin aspart over human insulin in ].<ref>{{cite journal | vauthors = Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Gerlach FM | title = Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | volume = 12 | issue = 12 | pages = CD013228 | date = December 2018 | pmid = 30556900 | pmc = 6517032 | doi = 10.1002/14651858.CD013228 }}</ref> It is thus unclear why the shifting of people from human insulin to insulin aspart has occurred.<ref>{{cite journal | vauthors = Cohen D, Carter P | title = How small changes led to big profits for insulin manufacturers | journal = BMJ | volume = 341 | pages = c7139 | date = December 2010 | pmid = 21159773 | doi = 10.1136/bmj.c7139 | s2cid = 30709912 }}</ref> In ] it appears to result in slightly better blood sugar control.<ref>{{cite journal | vauthors = Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Plank J, Pieber TR, Gerlach FM | title = Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | volume = 2016 | issue = 6 | pages = CD012161 | date = June 2016 | pmid = 27362975 | pmc = 6597145 | doi = 10.1002/14651858.CD012161 }}</ref>

== References ==
{{reflist}}

{{Oral hypoglycemics and insulin analogs}}
{{Portal bar | Medicine}}
{{Authority control}}

{{DEFAULTSORT:Insulin Aspart}}
]
]
]
]
]
]